349 related articles for article (PubMed ID: 37985748)
1. Pharmacomicrobiomics of cell-cycle specific anti-cancer drugs - is it a new perspective for personalized treatment of cancer patients?
Kaźmierczak-Siedlecka K; Bulman N; Ulasiński P; Sobocki BK; Połom K; Marano L; Kalinowski L; Skonieczna-Żydecka K
Gut Microbes; 2023 Dec; 15(2):2281017. PubMed ID: 37985748
[TBL] [Abstract][Full Text] [Related]
2. Pharmacomicrobiomics in Anticancer Therapies: Why the Gut Microbiota Should Be Pointed Out.
Conti G; D'Amico F; Fabbrini M; Brigidi P; Barone M; Turroni S
Genes (Basel); 2022 Dec; 14(1):. PubMed ID: 36672796
[TBL] [Abstract][Full Text] [Related]
3. Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies.
Panebianco C; Andriulli A; Pazienza V
Microbiome; 2018 May; 6(1):92. PubMed ID: 29789015
[TBL] [Abstract][Full Text] [Related]
4. Gut Microbiota Modulation of Efficacy and Toxicity of Cancer Chemotherapy and Immunotherapy.
Chrysostomou D; Roberts LA; Marchesi JR; Kinross JM
Gastroenterology; 2023 Feb; 164(2):198-213. PubMed ID: 36309208
[TBL] [Abstract][Full Text] [Related]
5. Gut microbiota modulation of chemotherapy efficacy and toxicity.
Alexander JL; Wilson ID; Teare J; Marchesi JR; Nicholson JK; Kinross JM
Nat Rev Gastroenterol Hepatol; 2017 Jun; 14(6):356-365. PubMed ID: 28270698
[TBL] [Abstract][Full Text] [Related]
6. Interaction between drugs and the gut microbiome.
Weersma RK; Zhernakova A; Fu J
Gut; 2020 Aug; 69(8):1510-1519. PubMed ID: 32409589
[TBL] [Abstract][Full Text] [Related]
7. Pharmacomicrobiomics: Influence of gut microbiota on drug and xenobiotic metabolism.
Dikeocha IJ; Al-Kabsi AM; Miftahussurur M; Alshawsh MA
FASEB J; 2022 Jun; 36(6):e22350. PubMed ID: 35579628
[TBL] [Abstract][Full Text] [Related]
8. Targeting gut microbiota for precision medicine: Focusing on the efficacy and toxicity of drugs.
Feng W; Liu J; Ao H; Yue S; Peng C
Theranostics; 2020; 10(24):11278-11301. PubMed ID: 33042283
[TBL] [Abstract][Full Text] [Related]
9. Pharmacomicrobiomics-Guided Precision Oncology: A New Frontier of P4 (Predictive, Personalized, Preventive, and Participatory) Medicine and Microbiome-Based Therapeutics.
Arga KY; Attia H; Aziz RK
OMICS; 2024 Jan; 28(1):5-7. PubMed ID: 38190279
[TBL] [Abstract][Full Text] [Related]
10. The role of gut microbiota in cancer treatment: friend or foe?
Cheng WY; Wu CY; Yu J
Gut; 2020 Oct; 69(10):1867-1876. PubMed ID: 32759302
[TBL] [Abstract][Full Text] [Related]
11. Pharmacomicrobiomics: a novel route towards personalized medicine?
Doestzada M; Vila AV; Zhernakova A; Koonen DPY; Weersma RK; Touw DJ; Kuipers F; Wijmenga C; Fu J
Protein Cell; 2018 May; 9(5):432-445. PubMed ID: 29705929
[TBL] [Abstract][Full Text] [Related]
12. Gut microbiota and cancer: How gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy.
Gori S; Inno A; Belluomini L; Bocus P; Bisoffi Z; Russo A; Arcaro G
Crit Rev Oncol Hematol; 2019 Nov; 143():139-147. PubMed ID: 31634731
[TBL] [Abstract][Full Text] [Related]
13. The impact of the host intestinal microbiome on carcinogenesis and the response to chemotherapy.
Wertman JN; Dunn KA; Kulkarni K
Future Oncol; 2021 Nov; 17(32):4371-4387. PubMed ID: 34448411
[TBL] [Abstract][Full Text] [Related]
14. Pharmacomicrobiomics and type 2 diabetes mellitus: A novel perspective towards possible treatment.
Jia L; Huang S; Sun B; Shang Y; Zhu C
Front Endocrinol (Lausanne); 2023; 14():1149256. PubMed ID: 37033254
[TBL] [Abstract][Full Text] [Related]
15. Pharmacomicrobiomics: The Holy Grail to Variability in Drug Response?
Sharma A; Buschmann MM; Gilbert JA
Clin Pharmacol Ther; 2019 Aug; 106(2):317-328. PubMed ID: 30937887
[TBL] [Abstract][Full Text] [Related]
16. Microbiota-drug interactions: Impact on metabolism and efficacy of therapeutics.
Wilkinson EM; Ilhan ZE; Herbst-Kralovetz MM
Maturitas; 2018 Jun; 112():53-63. PubMed ID: 29704918
[TBL] [Abstract][Full Text] [Related]
17. The impact of tumor and gut microbiotas on cancer therapy: Beneficial or detrimental?
Hekmatshoar Y; Rahbar Saadat Y; Hosseiniyan Khatibi SM; Ozkan T; Zununi Vahed F; Nariman-Saleh-Fam Z; Pourghassem Gargari B; Sunguroglu A; Zununi Vahed S
Life Sci; 2019 Sep; 233():116680. PubMed ID: 31344431
[TBL] [Abstract][Full Text] [Related]
18. Drug response in association with pharmacogenomics and pharmacomicrobiomics: towards a better personalized medicine.
Hassan R; Allali I; Agamah FE; Elsheikh SSM; Thomford NE; Dandara C; Chimusa ER
Brief Bioinform; 2021 Jul; 22(4):. PubMed ID: 33253350
[TBL] [Abstract][Full Text] [Related]
19. Gut microbiota contributes towards immunomodulation against cancer: New frontiers in precision cancer therapeutics.
Inamura K
Semin Cancer Biol; 2021 May; 70():11-23. PubMed ID: 32580023
[TBL] [Abstract][Full Text] [Related]
20. Impacts of the Human Gut Microbiome on Therapeutics.
Vázquez-Baeza Y; Callewaert C; Debelius J; Hyde E; Marotz C; Morton JT; Swafford A; Vrbanac A; Dorrestein PC; Knight R
Annu Rev Pharmacol Toxicol; 2018 Jan; 58():253-270. PubMed ID: 28968189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
